Generated: May 23, 2017
|Title:||Device for transdermal electrotransport delivery of fentanyl and sufentanil|
|Abstract:||The invention provides an improved electrotransport drug delivery system for analgesic drugs, namely fentanyl and sufentanil. The fentanyl/sufentanil is provided as a water soluble salt (e.g., fentanyl hydrochloride), preferably in a hydrogel formulation, for use in an electrotransport device (10). In accordance with the present invention, a transdermal electrotransport delivered dose of fentanyl/sufentanil is provided which is sufficient to induce analgesia in (e.g., adult) human patients suffering from moderate-to-severe pain as associated with major surgical procedures.|
|Inventor(s):||Southam; Mary (Menlo Park, CA), Bernstein; Keith J. (Somerville, NJ), Noorduin; Henk (Bergen op Zoom, NL)|
|Assignee:||Alza Corporation (Mountain View, CA)|
Patent Claim Types:|
see list of patent claims
|Delivery; Device; Formulation;|
|PCT Filed||May 22, 1996||PCT Application Number:||PCT/US96/07380|
|PCT Publication Date:||December 12, 1996||PCT Publication Number:||WO96/39222|
|Country||Document Number||Estimated Expiration||Supplementary Protection Certificate||SPC Country||SPC Expiration|
|European Patent Office||0836511||► Subscribe||91265||Luxembourg||► Subscribe|
|European Patent Office||0836511||► Subscribe||CA 2006 00019||Denmark||► Subscribe|
| This preview shows a limited data set|
Subscribe for full access, or try a Trial
The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.
Export unavailable in trial.
Subscribe for complete access.